Petri Bio LLC

LOS ANGELES, CA · Founded 2020 · CIK 0001818809 · Biotech · Private

UNCERTAIN - insufficient information

petribio.com →
Grants
$2.9M
5 awards
Sector median: 1
Raised
$255K
1 Form D · Oct 2021
60 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Live microbial therapeutics for enzyme replacement therapy against homocystinuria$361,931
Private capital raisedForm D · SEC$255,000
Federal grantDepartment of Health and Human Services · Phase I · Live microbial therapeutics for enzyme replacement therapy against homocystinuria$55,000
Federal grantDepartment of Health and Human Services · Phase II · Live microbial therapeutics: an enhanced treatment paradigm for classical homocystinuria$1,000,496
Federal grantDepartment of Health and Human Services · Phase II · Live microbial therapeutics: an enhanced treatment paradigm for classical homocystinuria$1,169,818
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1188SHIP OF THESEUS, LLC——
1189Bridge Therapeutics, Inc.—$321K
1190BioVaxys Technology Corp.—$301K
1191Petri Bio LLC—$255K
1192PreveCeutical Medical Inc.—$254K
1193KELIOMICS, INC.—$250K
1194ELF ZONE, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Shu LiDirector · Executive Officer · Promoter

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.